In the base-case analysis, ivosidenib, an inhibitor targeting mutant IDH1, was not cost-effective at NT$10,402 per 500 mg for previously treated patients with advanced ICC and IDH1 mutations. Here, IDH1 is linked to intrahepatic cholangiocarcinoma.